Bridgebio Aces Phase 3 Rare Disease Test, Clearing Path to Fda
Posted2 months agoActive2 months ago
fiercebiotech.comResearchstory
calmpositive
Debate
0/100
Rare Disease TreatmentPharmaceutical IndustryClinical Trials
Key topics
Rare Disease Treatment
Pharmaceutical Industry
Clinical Trials
BridgeBio's phase 3 trial for a rare disease treatment was successful, paving the way for potential FDA approval, with the community showing muted but positive interest.
Snapshot generated from the HN discussion
Discussion Activity
Light discussionFirst comment
6m
Peak period
1
0-1h
Avg / period
1
Key moments
- 01Story posted
Oct 27, 2025 at 12:49 PM EDT
2 months ago
Step 01 - 02First comment
Oct 27, 2025 at 12:55 PM EDT
6m after posting
Step 02 - 03Peak activity
1 comments in 0-1h
Hottest window of the conversation
Step 03 - 04Latest activity
Oct 27, 2025 at 12:55 PM EDT
2 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
Discussion (1 comments)
Showing 1 comments
randycupertinoAuthor
2 months ago
Exciting results for this rare genetic muscle-wasting disorder Limb-Girdle Muscular Dystrophy (LGMD2I/R9) trial, and sounds like the FDA is on board with the surrogate endpoint. Could be big validation for BridgeBio’s rare disease strategy.
View full discussion on Hacker News
ID: 45723256Type: storyLast synced: 11/17/2025, 8:05:44 AM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.